ARBUTUS BIOPHARMA CORP's ticker is ABUS and the CUSIP is 03879J100. A total of 124 filers reported holding ARBUTUS BIOPHARMA CORP in Q4 2021. The put-call ratio across all filers is 0.91 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $114,929 | -6.7% | 56,615 | +5.7% | 0.00% | – |
| Q2 2023 | $123,142 | -13.4% | 53,540 | +14.0% | 0.00% | – |
| Q1 2023 | $142,273 | +34.6% | 46,955 | +3.5% | 0.00% | – |
| Q4 2022 | $105,686 | +46.8% | 45,359 | +19.5% | 0.00% | – |
| Q3 2022 | $72,000 | -24.2% | 37,965 | +8.3% | 0.00% | – |
| Q2 2022 | $95,000 | +18.8% | 35,040 | +30.3% | 0.00% | – |
| Q1 2022 | $80,000 | -19.2% | 26,898 | +6.0% | 0.00% | – |
| Q4 2021 | $99,000 | -21.4% | 25,385 | -13.0% | 0.00% | – |
| Q3 2021 | $126,000 | +65.8% | 29,180 | +15.9% | 0.00% | – |
| Q2 2021 | $76,000 | -87.2% | 25,186 | -78.5% | 0.00% | – |
| Q4 2017 | $592,000 | -15.4% | 117,321 | +3.9% | 0.00% | – |
| Q3 2017 | $700,000 | +98.3% | 112,927 | +15.1% | 0.00% | – |
| Q2 2017 | $353,000 | +10.0% | 98,090 | -0.7% | 0.00% | – |
| Q1 2017 | $321,000 | – | 98,800 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Two Seas Capital LP | 825,569 | $3,211,000 | 2.46% |
| GREAT POINT PARTNERS LLC | 668,907 | $2,602,000 | 0.58% |
| JACOB ASSET MANAGEMENT OF NEW YORK LLC | 270,000 | $1,050,000 | 0.47% |
| QCM Cayman, Ltd. | 10,205 | $40,000 | 0.24% |
| Pitti Group Wealth Management, LLC | 50,000 | $195,000 | 0.22% |
| RTW INVESTMENTS, LP | 2,504,493 | $9,742,000 | 0.14% |
| Hudson Bay Capital Management LP | 1,805,700 | $7,024,000 | 0.07% |
| Quinn Opportunity Partners LLC | 276,485 | $1,076,000 | 0.07% |
| Kepos Capital LP | 200,000 | $778,000 | 0.06% |
| XTX Topco Ltd | 29,026 | $113,000 | 0.06% |